Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies-three-year observational study

被引:11
作者
Matsushita, Isao [1 ]
Motomura, Hiraku [1 ]
Seki, Eiko [1 ]
Kimura, Tomoatsu [1 ]
机构
[1] Univ Toyama, Dept Orthopaed Surg, Fac Med, 2630 Sugitani, Toyama 9300194, Japan
关键词
Etanercept; Infliximab; Radiographic progression; Rheumatoid arthritis; TNF-blocking therapy; Weight-bearing joint; PLUS METHOTREXATE; DOUBLE-BLIND; TRIAL; ETANERCEPT; DISABILITY; INFLIXIMAB; COMBINATION;
D O I
10.1080/14397595.2016.1227235
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The long-term effects of tumor necrosis factor (TNF)-blocking therapies on weight-bearing joints in patients with rheumatoid arthritis (RA) have not been fully characterized. The purpose of this study was to assess the radiographic changes of weight-bearing joints in patients with RA during 3-year of TNF-blocking therapies and to identify factors related to the progression of joint damage. Methods: Changes in clinical variables and radiological findings in 243 weight-bearing joints (63 hips, 54 knees, 71 ankles, and 55 subtalar joints) in 38 consecutive patients were investigated during three years of treatment with TNF-blocking agents. Multivariate logistic regression analysis was used to identify risk factors for the progression of weight-bearing joint damage. Results: Seventeen (14.5%) of proximal weight-bearing joints (hips and knees) showed apparent radiographic progression during three years of treatment, whereas none of the proximal weight-bearing joints showed radiographic evidence of improvement or repair. In contrast, distal weight-bearing joints (ankle and subtalar joints) displayed radiographic progression and improvement in 20 (15.9%) and 8 (6.3%) joints, respectively. Multivariate logistic analysis for proximal weight-bearing joints identified the baseline Larsen grade (p<0.001, OR:24.85, 95%CI: 5.07-121.79) and disease activity at one year after treatment (p=0.003, OR:3.34, 95%CI:1.50-7.46) as independent factors associated with the progression of joint damage. On the other hand, multivariate analysis for distal weight-bearing joints identified disease activity at one year after treatment (p<0.001, OR:2.13, 95%CI:1.43-3.18) as an independent factor related to the progression of damage. Conclusions: Baseline Larsen grade was strongly associated with the progression of damage in the proximal weight-bearing joints. Disease activity after treatment was an independent factor for progression of damage in proximal and distal weight-bearing joints. Early treatment with TNF-blocking agents and tight control of disease activity are necessary to prevent the progression of damage of the weight-bearing joints.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 21 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[3]   Radiographic damage of large joints in long-term rheumatoid arthritis and its relation to function [J].
Drossaers-Bakker, KW ;
Kroon, HM ;
Zwinderman, AH ;
Breedveld, FC ;
Hazes, JMW .
RHEUMATOLOGY, 2000, 39 (09) :998-1003
[4]   Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].
Emery, Paul ;
Breedveld, Ferdinand C. ;
Hall, Stephen ;
Durez, Patrick ;
Chang, David J. ;
Robertson, Deborah ;
Singh, Amitabh ;
Pedersen, Ronald D. ;
Koenig, Andrew S. ;
Freundlich, Bruce .
LANCET, 2008, 372 (9636) :375-382
[5]  
FUCHS HA, 1989, J RHEUMATOL, V16, P585
[6]  
Kirwan JR, 2001, J RHEUMATOL, V28, P881
[7]   Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [J].
Klareskog, L ;
van der Heijde, D ;
de Jager, JP ;
Gough, A ;
Kalden, J ;
Malaise, M ;
Mola, EM ;
Pavelka, K ;
Sany, J ;
Settas, L ;
Wajdula, J ;
Pedersen, R ;
Fatenejad, S ;
Sanda, M .
LANCET, 2004, 363 (9410) :675-681
[8]   Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate -: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes [J].
Landewe, Robert ;
van der Heijde, Desiree ;
Klareskog, Lars ;
van Vollenhoven, Ronald ;
Fatenejad, Saeed .
ARTHRITIS AND RHEUMATISM, 2006, 54 (10) :3119-3125
[9]   RADIOGRAPHIC EVALUATION OF RHEUMATOID-ARTHRITIS AND RELATED CONDITIONS BY STANDARD REFERENCE FILMS [J].
LARSEN, A ;
DALE, K ;
EEK, M .
ACTA RADIOLOGICA-DIAGNOSIS, 1977, 18 (04) :481-491
[10]   Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].
Lipsky, PE ;
van der Heijde, DMFM ;
St Clair, EW ;
Furst, DE ;
Breedveld, FC ;
Kalden, JR ;
Smolen, JS ;
Weisman, M ;
Emery, P ;
Feldmann, M ;
Harriman, GR ;
Maini, RN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602